An observational study in Hemophilia A, sponsored by Swedish Orphan Biovitrum. Completed at 36 sites in 9 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2024-10-02.
Sponsored by Swedish Orphan Biovitrum · Observational
The purpose of the study is to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A over a 24-month prospective period. Data will also be collected for a 12 month retrospective period.
885 studies on the registry are indexed under Hemophilia A; 139 are open to participants now.
This study's enrollment of 361 is above the median of 80 across 322 observational studies indexed under Hemophilia A.
Browse Hemophilia A studies →Swedish Orphan Biovitrum is the lead sponsor of 80 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Male patients with a diagnosis of haemophilia A prescribed prophylactic treatment with Elocta or conventional factor product
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Elocta will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
Drug: efmoroctocog alfa
Conventional factor VIII products will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
Drug: Factor VIII
extended half-life factor VIII product
Also known as: Elocta
conventional factor VIII product
Annualised bleeding rate (ABR)
Time frame: 24 months
Annualised injection frequency
Time frame: 24 months
Annualised factor consumption (International Unit [IU])
Time frame: 24 months
Plan to share: Undecided
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.